| Literature DB >> 34920686 |
Marilou Kiely1,2,3, Thowiba Mansour3, Nicholas Brousseau1,2,3, Ellen Rafferty4, Yuba Raj Paudel5, Manish Sadarangani6,7, Lawrence W Svenson8,9,10,11, Joan L Robinson12, Arnaud Gagneur13, S Michelle Driedger14, Shannon E MacDonald15.
Abstract
Response measures to mitigate the coronavirus disease 2019 pandemic impacted access to routine vaccination services. We evaluate the impact of the pandemic on routine infant vaccination uptake by comparing vaccination coverage, vaccine delays and doses administered in 2019 and 2020, in Quebec, Canada. Using a population-based vaccination registry, we compared vaccination coverage at 3, 5, 13 and 19 months of age between 2019 and 2020 cohorts each month from January to November. For vaccine delays, we measured the cumulative proportion vaccinated in each targeted cohort monthly. We also compared the measles-containing vaccines administered before 24 months of age between the same period in 2019 and 2020. A decline in vaccination coverage and children vaccinated on time was observed in all cohorts during the first months of the pandemic. The greatest impact was observed for the 18-month vaccination visit with a difference in vaccination coverage between both cohorts of 30.9% in May. Measles-containing doses administered during the first months of the pandemic were lower in 2020 compared with 2019: -21.1% in March (95%CI-21.6;-20.4), and -39.2% in April (95%CI-40.0;-38.2). After May, the coverage increased for all cohorts to reach pre-pandemic levels after a few months for most target ages. Routine childhood vaccinations were affected during the first months of the pandemic, but catch-up occurred thereafter and vaccination coverage in affected cohorts were very close to levels of 2019 after a few months of follow-up. Real-time monitoring of childhood vaccination is essential but also for other vaccination programs, severely affected by the pandemic.Entities:
Keywords: COVID-19 pandemic; Vaccine coverage; early childhood; impact; vaccine delay
Mesh:
Substances:
Year: 2021 PMID: 34920686 PMCID: PMC9553134 DOI: 10.1080/21645515.2021.2007707
Source DB: PubMed Journal: Hum Vaccin Immunother ISSN: 2164-5515 Impact factor: 4.526
Quebec vaccination schedule up to 24 months of age as applicable for children in this study
| Vaccination visits | Children born before June 1, 2019 | Children born since June 1, 2019 |
|---|---|---|
| 2 months | DTaP-HB-IPV-Hib | DTaP-HB-IPV-Hib |
| PCV | PCV | |
| Rotavirus | Rotavirus | |
| 4 months | DTaP-HB-IPV-Hib | DTaP-HB-IPV-Hib |
| PCV | PCV | |
| Rotavirus | Rotavirus | |
| 6 months | DTaP-IPV-Hib | - |
| 12 months | MMR or MMRV | DTaP-IPV-Hib |
| PCV | PCV | |
| Men-C-C | MMRV | |
| 18 months | MMRV | HAHB |
Abbreviations: DTaP-HB-IPV-Hib: Diphtheria, tetanus, pertussis, hepatitis B, polio, and Haemophilus influenzae type b vaccine.
PCV: Pneumococcal conjugate vaccine.
DTaP-IPV-Hib: Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b vaccine.
MMR ± V: Measles, mumps, rubella and varicella vaccine.
Men-C-C: Meningococcal conjugate serogroup C vaccine.
HAHB: Combined hepatitis A and B vaccine
Figure 1.Vaccination coverage of children who turned the milestone ages each month from January to November in 2019 and 2020. VC assessed by 3 months old (Panel A) and 5 months old (Panel B) for the first and second doses of DTaP and rotavirus vaccines scheduled at 2 and 4 months old. *P-value < .05 for the comparison in VC between 2019 and 2020 using a chi-square test.
Figure 2.Vaccination coverage of children who turned the milestone ages each month from January to November in 2019 and 2020. VC assessed by 13 months old (Panel A) for the first dose of the measles-containing vaccine and for the third dose of the pneumococcal vaccine scheduled at 12 months old, and by 19 months old (Panel B) for the DTaP vaccine and the measles-containing vaccine (second doses) scheduled at 18 months old. *P-value < .05 for the comparison in VC between 2019 and 2020 using a chi-square test.
Figure 3.Cumulative proportion of children vaccinated for the first and second dose of DTaP-containing vaccine among children turning 2 months old (Panel A) and 4 months old (Panel B) in March 2019 and 2020 (left) and in April 2019 and 2020 (right). Bars represent 95% Confidence intervals calculated with the exact method.
Figure 4.Cumulative proportion of children vaccinated for the first and second dose of measles-containing vaccine among children turning 12 months old (Panel A) and 18 months old (Panel B) in March 2019 and 2020 (left) and in April 2019 and 2020 (right). Bars represent 95% Confidence intervals calculated with the exact method.
Doses of measles-containing vaccines (MMR or MMRV) administered before 24 months of age in 2020 compared with 2019, by month from January to November
| Month | Doses administered 2019 | Doses administered 2020 | Difference 2020–2019 | Relative diff 2020–2019 (95% CI)* |
|---|---|---|---|---|
| January | 11783 | 13069 | 1286 | 10.9 (10.4; 11.4) |
| February | 11609 | 11966 | 357 | 3.1 (2.8; 3.4) |
| March | 14766 | 11667 | −3099 | −21.0 (−21.6; −20.4;) |
| April | 11433 | 6954 | −4479 | −39.2 (−40.0; −38.2) |
| May | 11861 | 13391 | 1530 | 12.9 (12.4; 13.6) |
| June | 13818 | 11864 | −1954 | −14.1 (−14.8; −13.6;) |
| July | 11418 | 12472 | 1054 | 9.2 (8.8; 9.8) |
| August | 11650 | 14721 | 3071 | 26.4 (25.6; 27.2) |
| September | 14193 | 11330 | −2863 | −20.2 (−20.8; −19.6) |
| October | 11046 | 10828 | −218 | −2.0 (−2.2; −1.8) |
| November | 11447 | 11027 | −420 | −3.7 (−4.0; −3.4) |
*Exact Method for 95% CI.
| WHO | World Health Organization |
| COVID-19 | Coronavirus Disease of 2019 |
| SARS-CoV-2 | Severe Acute Respiratory Syndrome Coronavirus- 2 |
| NACI | National Advisory Committee on Immunization |
| QIC | Quebec Immunization Committee |
| VC | Vaccination Coverage |
| PCV | Pneumococcal Conjugate Vaccine |
| DTaP-HB-IPV-Hib | Diphtheria, tetanus, pertussis, hepatitis B, polio, and |
| DTaP-IPV-Hib | Diphtheria, Tetanus, Pertussis, Polio, and |
| MMR ± V | Measles, Mumps, Rubella ± Varicella vaccine |
| Men-C-C | Meningococcal Conjugate serogroup C vaccine |
| HAHB | Combined hepatitis A and B vaccine |